On May 29, 2024 ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, reported that management will participate in the Jefferies Global Healthcare Conference (Press release, ALX Oncology, MAY 29, 2024, View Source [SID1234643771]). Details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Format: Fireside chat with analyst, Michael Yee and 1×1 Investor Meetings
Date: Wednesday, June 5, 2024
Time: 1:00 PM ET
Location: New York, NY
Webcast link: Available here

The live webcast of the Jefferies fireside chat can be accessed by visiting the Investors section of ALX Oncology’s website at Events under the News and Events tab. A replay of the webcast will be archived for up to 90 days following the fireside chat date.